About Pharm-Olam
Pharm-Olam is a company based in Houston (United States) founded in 1994. The company has 177 employees. Pharm-Olam offers products and services including Clinical Development, Regulatory Strategy, and Pharmacovigilance. Pharm-Olam operates in a competitive market with competitors including Celgene, Syneos Health, Medelis WCCT Global, Emmes and Parexel, among others.
- Headquarter Houston, United States
- Employees 177
- SectorsHealthcare
- Email••••••••
- Website pharm-olam.com
- Social LinkedIn
- Legal Name Pharm-Olam International (India) Private Limited
- Date of Incorporation 27 Nov, 2002
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹47.87 Cr
FY 2025 · +4% YoY
- Net Profit₹3.22 Cr
FY 2025 · 7% margin
- EBITDA₹6.18 Cr
FY 2025 · 13% margin
- Investors
- Employee Count177
Associated legal entities of Pharm-Olam
Pharm-Olam operates through Allucent (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Allucent (India) Private Limited CIN U51397KA2002PTC031282 | Active | 27 Nov 2002 | Bangalore, Karnataka | ₹47.9 Cr | 177 | 2 | View details |
Products & Services of Pharm-Olam
Pharm-Olam offers a comprehensive portfolio of products and services, including Clinical Development, Regulatory Strategy, and Pharmacovigilance.
Supports clinical trials and patient recruitment for drug testing
Assists with regulatory submissions and compliance for biotech firms
Monitors drug safety and post-marketing surveillance globally
Funding Insights of Pharm-Olam
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Pharm-Olam with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | – | Private Equity Round | – | – |
1 investors in total: 1 institutional.
Investors in Pharm-Olam
Pharm-Olam has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Quad-C.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Buyouts are executed by Quad-C in the private equity sector. | – | quadcmanagement.com | Charlottesville, United States |
Investor details for Pharm-Olam
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Allucent (India) Private Limited (Pharm-Olam)
Allucent (India) Private Limited is the primary company behind Pharm-Olam. The board of Allucent (India) Private Limited currently have 2 directors; the longest-serving is Sivakumar Subramanian, appointed in 2023. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sivakumar Subramanian DIN 00969866 | Director | 21 Feb 2023 | 3 yrs 7 mo | Allucent (India) Private Limited |
| Howard Richard Brand DIN 11312380 | Additional Director | 29 Sep 2025 | 1 yr | Allucent (India) Private Limited |
Financials of Pharm-Olam
Figures of Allucent (India) Private Limited, the primary company behind Pharm-Olam, for FY 2025. Revenue was ₹47.87 Cr (+4% year on year). Net profit was ₹3.22 Cr (7% margin). EBITDA was ₹6.18 Cr (13% margin). Revenue has grown at a compounded annual rate of +33% over three years and +27% over five years.
- ₹47.87 CrRevenue · FY 2025 · +4% YoY
- ₹3.22 CrNet profit · 7% margin
- ₹6.18 CrEBITDA · 13% margin
- ₹1 LakhPaid-up capital
- 177Employees (provident fund records)
- +33%Revenue CAGR, 3 years
- +27%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Allucent (India) Private Limited are on its company page.
Detailed financial statements for Pharm-Olam
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Pharm-Olam
2 dated milestones of Pharm-Olam across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Pharm-Olam is founded.
- Funding First funding round.
Competitors of Pharm-Olam
Pharm-Olam operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, Syneos Health, Medelis WCCT Global, Emmes and Parexel, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. | |
| syneoshealth.com | 1984 | Raleigh, United States | – | 29,395 | CRO clinical development services are provided by Syneos Health. | |
| wcct.com | 1998 | Cypress, United States | $17M | 229 | Full-service CRO expertise in influenza and oncology research is offered. | |
| emmes.com | 1977 | United States | – | 195 | Outsourced contract research organization services are provided to clients. | |
| parexel.com | 1983 | Waltham, United States | – | – | Full-service clinical research organization services are provided globally by Parexel. | |
| prahs.com | 1976 | Raleigh, United States | – | 21 | Global full-service CRO services are delivered in over 80 countries. | |
| veristat.com | 1994 | Southborough, United States | – | 7 | Clinical trials and regulatory submissions are supported as a CRO. | |
| clinchoice.com | 1995 | Fort Washington, United States | $212M | 478 | CRO focused on data management, regulatory affairs and consulting services |
Detailed competitors of Pharm-Olam
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pharm-Olam
Websites that share an audience with Pharm-Olam (pharm-olam.com).
Websites whose visitors overlap most with Pharm-Olam. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
abbott.co.in | abbott.co.in | 100% | – | #1,717,804 | – |
| vimta.com | 100% | 294.1K | #145,084 | View details | |
jrfonline.com | jrfonline.com | 100% | – | – | – |
| ipcalabs.com | 100% | – | #6,089,785 | View details | |
| quartesian.com | 100% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Pharm-Olam
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Pharm-Olam
Complete news archive for Pharm-Olam
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Pharm-Olam
10 companies that operate in the same segment as Pharm-Olam (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pharm-Olam
Pharm-Olam was founded in 1994 and raised its 1st funding round 23 years after it was founded.
Pharm-Olam is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Pharm-Olam has 177 employees.
The primary company behind Pharm-Olam, Allucent (India) Private Limited, reported revenue of ₹47.87 Cr for FY 2025, up 4% year on year.
Pharm-Olam is a CRO with 27 offices and has supported clinical trials in 60 countries across all continents. Their full-service offerings such as regulatory, clinical, and project management services are offered across the majority of the 40 countries. In addition, they offer Medical Writing, Data Management, Biostatisticians, Pharmacovigilance, and Medical Monitoring services from North America, Europe, and India. Their services include regulatory issues and the conduct of clinical trials in devices, ranging from diagnostic products, active medical devices, and device delivery systems. They cater to 15 therapeutic areas which include cardiovascular and infectious diseases, oncology and pediatric studies. They also offer rescue studies, orphan drug trial services, and non-interventional clinical trial services.
Pharm-Olam's top competitors include Emmes, Syneos Health and ClinChoice.
Pharm-Olam offers Clinical Development, Regulatory Strategy, and Pharmacovigilance.
Pharm-Olam has 1 investor. Key investors include Quad-C.
Pharm-Olam operates through Allucent (India) Private Limited.
The legal entities of Pharm-Olam currently have 2 directors, including Sivakumar Subramanian, Howard Richard Brand.